Related Experiment Video
Updated: Jul 15, 2026

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
Published on: August 23, 2024
Membranous nephropathy: when and how to treat
1Department of Medicine, Queen Mary Hospital, University of Hong Kong, Hong Kong. knlai@hkucc.hku.hk
Idiopathic membranous nephropathy treatment varies, necessitating risk-stratified strategies. Early immunosuppressive therapy is crucial for high-risk patients to prevent kidney damage.
Area of Science:
- Nephrology
- Immunology
Background:
- Idiopathic membranous nephropathy (IMN) treatment lacks consensus due to variable patient outcomes.
- Risk stratification is essential to guide therapy, distinguishing between conservative management and immunosuppressive agents.
Discussion:
- Current treatment standards often involve combination therapy with steroids and alkylating agents.
- The optimal timing and intensity of immunosuppression for IMN remain subjects of ongoing research and debate.
Key Insights:
- A rational treatment approach for IMN requires careful patient risk assessment.
- Identifying patients who will benefit most from immunosuppressive therapy is critical for improving renal outcomes.
Outlook:
- Further investigation into novel immunosuppressive agents and treatment protocols for IMN is warranted.
- Developing standardized risk-assessment tools will enhance personalized treatment strategies for idiopathic membranous nephropathy.
Related Concept Videos
Nephrotic Syndrome II : Assessment and Medical Management
Chronic Kidney Disease III: Interprofessional Care
Diabetic Nephropathy
Nephrotic Syndrome III : Nursing Management
Nephrotic Syndrome I : Introduction
Acute Kidney Injury V: Interprofessional Care

